Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells

Molecular Carcinogenesis

Volumn 53, Issue 3, 2014, Pages 169-180

  Kavitha, Chandagirikoppal V ^a   Deep, Gagan ^a,b   Gangar, Subhash C ^a   Jain, Anil K ^a   Agarwal, Chapla ^a,b   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

NFATc1; Osteoclastogenesis; Prostate cancer; RANK ligand; Silibinin

Indexed keywords

NFATC1; OSTEOCLASTOGENESIS; PROSTATE CANCER; RANK LIGAND; SILIBININ;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; MACROPHAGES; MALE; MICE; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PROSTATIC NEOPLASMS; RANK LIGAND; SILYMARIN; TRANSCRIPTION FACTOR AP-1;

EID: 84894279317     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21959     Document Type: Article

References (59)

1. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003; 34:646-653.
2. Saad F, Markus R, Goessl C. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases. BJU Int 2008; 101:1071-1075.
3. Msaouel P, Pissimissis N, Halapas A, Koutsilieris M. Mechanisms of bone metastasis in prostate cancer: Clinical implications. Best Pract Res Clin Endocrinol Metab 2008; 22:341-355.
4. Buijs JT, van der Pluijm G. Osteotropic cancers: From primary tumor to bone. Cancer Lett 2009; 273:177-193.
5. Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009; 310:71-81.
6. Clarke NW, Hart CA, Brown MD. Molecular mechanisms of metastasis in prostate cancer. Asian J Androl 2009; 11:57-67.
7. Ibrahim T, Flamini E, Fabbri L, et al. Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model. Tumori 2009; 95:291-297.
8. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289:1504-1508.
9. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007; 40:251-264.
10. Body JJ. Denosumab for the management of bone disease in patients with solid tumors. Expert Rev Anticancer Ther 2012; 12:307-322.
11. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011; 377:813-822.
12. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-593.
13. Lee ZH, Kim HH. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 2003; 305:211-214.
14. Feng X. RANKing intracellular signaling in osteoclasts. IUBMB Life 2005; 57:389-395.
15. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB. Anticancer potential of silymarin: From bench to bed side. Anticancer Res 2006; 26:4457-4498.
16. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006; 124:491-504.
17. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: A comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 2006; 25:1053-1069.
18. Singh RP, Raina K, Deep G, Chan D, Agarwal R. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 2009; 15:613-621.
19. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008; 68:6822-6830.
20. Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 2008; 14:7773-7780.
21. Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007; 25:139-146.
22. Flaig TW, Glode M, Gustafson D, et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010; 70:848-855.
23. Muller MM, Schreiber E, Schaffner W, Matthias P. Rapid test for in vivo stability and DNA binding of mutated octamer binding proteins with 'mini-extracts' prepared from transfected cells. Nucleic Acids Res 1989; 17:6420.
24. Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: Induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res 1998; 4:1055-1064.
25. Kaur M, Velmurugan B, Tyagi A, et al. Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther 2009; 8:2366-2374.
26. Agarwal C, Singh RP, Dhanalakshmi S, et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003; 22:8271-8282.
27. Deep G, Oberlies NH, Kroll DJ, Agarwal R. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene 2008; 27:3986-3998.
28. Singh RP, Dhanalakshmi S, Mohan S, Agarwal C, Agarwal R. Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-kappaB in mouse epidermal JB6 cells. Mol Cancer Ther 2006; 5:1145-1153.
29. Deep G, Raina K, Singh RP, Oberlies NH, Kroll DJ, Agarwal R. Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: Comparison with silymarin and silibinin. Int J Cancer 2008; 123:2750-2758.
30. Kim JL, Kang SW, Kang MK, et al. Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts. J Cell Biochem 2012; 113:247-259.
31. Hiasa M, Abe M, Nakano A, et al. GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). Blood 2009; 114:4517-4526.
32. Hemingway F, Taylor R, Knowles HJ, Athanasou NA. RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone 2011; 48:938-944.
33. Kim JH, Jin HM, Kim K, et al. The mechanism of osteoclast differentiation induced by IL-1. J Immunol 2009; 183:1862-1870.
34. Kim JH, Kim K, Jin HM, et al. Silibinin inhibits osteoclast differentiation mediated by TNF family members. Mol Cells 2009; 28:201-207.
35. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3:889-901.
36. Zhao Q, Wang X, Liu Y, He A, Jia R. NFATc1: Functions in osteoclasts. Int J Biochem Cell Biol 2010; 42:576-579.
37. Kim Y, Sato K, Asagiri M, Morita I, Soma K, Takayanagi H. Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J Biol Chem 2005; 280:32905-32913.
38. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 2000; 275:31155-31161.
39. Rucci N, Teti A. Osteomimicry: How tumor cells try to deceive the bone. Front Biosci (Schol Ed) 2010; 2:907-915.
40. Josson S, Matsuoka Y, Chung LW, Zhau HE, Wang R. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol 2010; 21:26-32.
41. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
42. Aapro M, Saad F, Costa L. Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist 2010; 15:1147-1158.
43. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379:39-46.
44. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: Molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 2010; 29:447-463.
45. Deep G, Gangar SC, Agarwal C, Agarwal R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila) 2011; 4:1222-1232.
46. Tyagi A, Singh RP, Ramasamy K, et al. Growth inhibition and regression of lung tumors by silibinin: Modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (PhilaPa) 2009; 2:74-83.
47. Atanga E, Dolder S, Dauwalder T, Wetterwald A, Hofstetter W. TNFalpha inhibits the development of osteoclasts through osteoblast-derived GM-CSF. Bone 2011; 49:1090-1100.
48. Qian Y, Huang HZ. The role of RANKL and MMP-9 in the bone resorption caused by ameloblastoma. J Oral Pathol Med 2010; 39:592-598.
49. Tu Q, Zhang J, Dong LQ, et al. Adiponectin inhibits osteoclastogenesis and bone resorption via APPL1-mediated suppression of Akt1. J Biol Chem 2011; 286:12542-12553.
50. Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005; 331:520-526.
51. Wang Y, Nishida S, Elalieh HZ, Long RK, Halloran BP, Bikle DD. Role of IGF-I signaling in regulating osteoclastogenesis. J Bone Miner Res 2006; 21:1350-1358.
52. Coelho LF, Magno de Freitas Almeida G, Mennechet FJ, Blangy A, Uze G. Interferon-alpha and -beta differentially regulate osteoclastogenesis: Role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci USA 2005; 102:11917-11922.
53. Morita Y, Ono A, Serizawa A, et al. Purification and identification of lactoperoxidase in milk basic proteins as an inhibitor of osteoclastogenesis. J Dairy Sci 2011; 94:2270-2279.
54. Braun T, Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther 2011; 13:235.
55. Adamopoulos IE, Xia Z, Lau YS, Athanasou NA. Hepatocyte growth factor can substitute for M-CSF to support osteoclastogenesis. Biochem Biophys Res Commun 2006; 350:478-483.
56. Cadosch D, Gautschi OP, Chan E, Simmen HP, Filgueira L. Titanium induced production of chemokines CCL17/TARC and CCL22/MDC in human osteoclasts and osteoblasts. J Biomed Mater Res A 2010; 92:475-483.
57. Takamatsu Y, Simmons PJ, Moore RJ, Morris HA, To LB, Levesque JP. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood 1998; 92:3465-3473.
58. Miyazaki T, Katagiri H, Kanegae Y, et al. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 2000; 148:333-342.
59. Takayanagi H. The role of NFAT in osteoclast formation. Ann NY Acad Sci 2007; 1116:227-237.